top of page


Guided by Leaders with a Strong Track Record of Execution

Comprised of leaders from academia, life science companies, and emerging biotechs, our team shares a deep connection to the rare epilepsy community and a passion for changing the way epileptic drugs are discovered and developed. 

Epygenix Alex Yang 2022_edited.jpg

Alex Yang

Interim CEO and Chair of the Board

Alex Yang, J.D., L.L.M. is the original funder of Epygenix Therapeutics, Inc. and the CEO/owner of Mstone Partners, which serves as the major shareholder of Epygenix Therapeutics, Inc. Alex also serves as the CEO of Curyx Partners, a biotech incubation platform, which has set up a number of drug development companies in both pre-clinical and clinical stages.

Alex has over 25 years of experience in advising and executing fund formation, cross-border transactions, and a diverse pool of investment experiences in multiple industry sectors. He currently serves investment and risk committee member roles for various regional and country-focused private equity funds. Alex is formerly a managing partner at Kim & Chang and was a partner at the Ernst & Young Hong Kong office leading regional financial services practice, including banking and capital markets, asset management, and insurance.

Alex formerly worked at the Morgan Stanley Hong Kong Office in the capacity of its Asia Private Equity and In-house Counsel, focused on buy-outs and grow-capital investments, real estate, special situation, and infrastructure transactions across Asia. He also worked at Coopers & Lybrand and Ernst & Young New York offices in their international tax and consulting divisions.

Alex graduated from New York University School of Law with both J.D. and L.L.M. degrees and a bar with the State of New York and received an undergraduate degree from Binghamton University with Economics.


Lorianne Masuoka, MD

Chief Medical Officer

Dr. Masuoka has more than 25 years of experience building and expanding high value pipelines in the biopharmaceutical industry that have resulted in drug approvals and strategic alliances. She is a board-certified neurologist who has successfully created and overseen high performing teams to lead the clinical development of new medicines, with a focus in multiple sclerosis, oncology, and epilepsy. Dr. Masuoka served as Chief Medical Officer of Marinus Pharmaceuticals, Cubist Pharmaceuticals (now Merck), and Nektar Therapeutics where, as a member of executive management, she managed teams in the areas of clinical research, pharmacovigilance, biostatistics and data management, regulatory affairs, and clinical operations. Previously, she held various roles of increasing responsibility at FivePrime Therapeutics (now Amgen) and Chiron (now Novartis). In addition to her executive roles, Dr. Masuoka most recently served as a Board member at Pfenex Inc. (now Ligand) and serves as a Board member at Opiant Pharmaceuticals.

Dr. Masuoka received her medical degree from the University of California, Davis, where she also completed her residency in neurology. She completed her epilepsy fellowship at Yale University and is board certified by the American Board of Psychiatry and Neurology.


G. Michael Landis, CPA

Chief Financial Officer

Michael is a highly accomplished financial executive who brings an over 25-year track record of public company expertise, capital market transactions, investor relations, and financial reporting. Prior to joining Epygenix, Michael was most recently the Chief Financial Officer at Avisa Diagnostics Inc., a publicly traded medical device company. While there, he was responsible for strategic and tactical finance initiatives and was directly involved with investor relations and capital raising activities. Before that, he served as Principal Accounting Officer and Treasurer at Lannett Company Inc., a publicly traded pharmaceutical company, where he led acquisitions and related financing activities and was a member of the executive team that successfully completed a $1.2 billion acquisition. Michael was also actively involved in the initial Public Offering (IPO) process in previous financial leadership roles at companies including Akrion Inc. and AlliedBarton Security Services, LLC. Earlier, he worked at various other publicly traded companies after beginning his career within the Big Four public accounting firms. Michael received his Bachelors in Accounting from Franklin & Marshall College and is an active Certified Public Accountant.

bottom of page